$220.61 1.2 0.5%
Last Trade - 17/01/20
| Market Cap | £6.46bn |
| Enterprise Value | £6.72bn |
| Revenue | £564.5m |
| Position in Universe | 891st / 6415 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences reporting segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology community. The Protein Sciences segment also provides an array of platforms useful in various areas of protein analysis. The Diagnostics and Genomics reporting segment provides blood chemistry and blood gas quality controls, hematology instrument controls, diagnostics immunoassays and other bulk and custom reagents for the in vitro diagnostic market.
| Last Annual | June 30th, 2019 |
| Last Interim | September 30th, 2019 |
| Incorporated | July 17, 1981 |
| Public Since | February 9, 1989 |
| No. of Shareholders: | 43,000 |
| No. of Employees: | 2,250 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | S&P 400 Mid Cap , Nasdaq Composite , S&P Composite 1500 , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 38,112,184 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 614 McKinley Pl NE, MINNEAPOLIS, 55413-2610, United States |
| Web | http://www.techne-corp.com/ |
| Phone | +1 612 3798854 |
| Contact | David Clair (IR Contact Officer) |
| Auditors | KPMG LLP |
